Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue International Journal of Cancer Année : 2023

Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients

Ziling Mao
Jacqueline Roshelli Baker
  • Fonction : Auteur
Masayoshi Takeuchi
  • Fonction : Auteur
Hideyuki Hyogo
  • Fonction : Auteur
A. Marie Tjønneland
Anne Kirstine Eriksen
  • Fonction : Auteur
Verena Andrea Katzke
  • Fonction : Auteur
Rudolf J. Kaaks
  • Fonction : Auteur
Matthias Bernd Schulze
Domenico Palli
  • Fonction : Auteur
Sabina Sieri
Maria de Magistris
  • Fonction : Auteur
Rosario Tumino
Carlotta Sacerdote
Jeroen W.G. Derksen
  • Fonction : Auteur
Inger Torhild Gram
  • Fonction : Auteur
Guri Skeie
Torkjel Manning Sandanger
  • Fonction : Auteur
José Ramón Quirós
  • Fonction : Auteur
Marta Crous-Bou
Maria José Sánchez
Pilar Amiano
  • Fonction : Auteur
Sandra Milena Colorado-Yohar
Marcela M. Guevara
Sophia Harlid
Ingegerd Johansson
  • Fonction : Auteur
Aurora Perez-Cornago
Alicia K. Heath
  • Fonction : Auteur
Elom Kouassivi Aglago
  • Fonction : Auteur
Veronika Fedirko
  • Fonction : Auteur correspondant
  • PersonId : 1256819

Connectez-vous pour contacter l'auteur

Résumé

Glyceraldehyde-derived advanced glycation end products (glycer-AGEs) could contribute to colorectal cancer development and progression due to their pro-oxidative and pro-inflammatory properties. However, the association of glycer-AGEs with mortality after colorectal cancer diagnosis has not been previously investigated. Circulating glycer-AGEs were measured by competitive ELISA. Multivariable Cox proportional hazards models were used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for associations of circulating glycer-AGEs concentrations with CRC-specific and all-cause mortality among 1034 colorectal cancer (CRC) cases identified within the European Prospective Investigation into Cancer and Nutrition (EPIC) study between 1993 and 2013. During a mean of 48 months of follow-up, 529 participants died (409 from CRC). Glycer-AGEs were statistically significantly positively associated with CRC-specific (HRQ5 vs Q1 = 1.53, 95% CI: 1.04-2.25, Ptrend =.002) and all-cause (HRQ5 vs Q1 = 1.62, 95% CI: 1.16-2.26, Ptrend <.001) mortality among individuals with CRC. There was suggestion of a stronger association between glycer-AGEs and CRC-specific mortality among patients with distal colon cancer (per SD increment: HRproximal colon = 1.02, 95% CI: 0.74-1.42; HRdistal colon = 1.51, 95% CI: 1.20-1.91; Peffect modification =.02). The highest HR was observed among CRC cases in the highest body mass index (BMI) and glycer-AGEs category relative to lowest BMI and glycer-AGEs category for both CRC-specific (HR = 1.78, 95% CI: 1.02-3.01) and all-cause mortality (HR = 2.15, 95% CI: 1.33-3.47), although no statistically significant effect modification was observed. Our study found that prediagnostic circulating glycer-AGEs are positively associated with CRC-specific and all-cause mortality among individuals with CRC. Further investigations in other populations and stratifying by tumor location and BMI are warranted.
Fichier non déposé

Dates et versions

hal-04106328 , version 1 (25-05-2023)

Licence

Copyright (Tous droits réservés)

Identifiants

Citer

Ziling Mao, Jacqueline Roshelli Baker, Masayoshi Takeuchi, Hideyuki Hyogo, A. Marie Tjønneland, et al.. Prediagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients. International Journal of Cancer, 2023, 152 (11), pp.2257-2268. ⟨10.1002/ijc.34449⟩. ⟨hal-04106328⟩
16 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More